What is liraglutide and how does it work?

What is liraglutide?

Liraglutide is the active ingredient in a once-daily injection developed by Novo Nordisk. It belongs to a group of medicines called GLP-1 receptor agonists, which copy a gut hormone the body releases after eating.

It is given as a subcutaneous injection, meaning into the fat layer just under the skin of the stomach, thigh or upper arm. In South Africa it is a Schedule 4 medicine, so it always requires a doctor's assessment and authorisation, and it is dispensed by licensed pharmacies only. Liraglutide sits within the wider family of GLP-1 treatment.

The name people search for is often the brand rather than the molecule. Liraglutide is the generic name; the brands built on it are covered below. Knowing the molecule helps, because the same active ingredient behaves the same way whatever the box says.

How does liraglutide work?

Liraglutide activates GLP-1 receptors in the brain and gut. GLP-1 is a hormone released after meals that tells the body it has eaten. By copying it, liraglutide slows how quickly the stomach empties, reduces appetite and helps you feel full on less food.

It also prompts the pancreas to release insulin when blood sugar is high, which is why the same molecule is used for type 2 diabetes. For weight, the appetite effect is the key one: eating less over time is what drives the weight change. It is not a fat burner and does not work without diet and activity changes.

Liraglutide has a relatively short action in the body, lasting around a day, which is why it is injected daily rather than weekly. The newer medicines in this class were engineered to last long enough for once-weekly dosing, but the underlying appetite mechanism is the same idea.

The appetite effect is worth understanding because it explains the routine. Because liraglutide reduces hunger rather than blocking fat, it works best when meals are planned around a smaller appetite: regular protein, enough fluid and modest portions. People who lean on that window tend to tolerate the medicine better than those who fight it, which is why diet and activity support sit inside the plan rather than beside it.

What is liraglutide sold as?

Liraglutide is sold under two brand names, at different doses and for different uses.

The two are not interchangeable, even though they contain the same molecule, because they are dosed differently and registered for different purposes. For South African availability and price of the weight-management brand, see is Saxenda available in South Africa.

Why do Victoza and Saxenda get mixed up?

Because they are the same molecule wearing two coats. Novo Nordisk sells liraglutide as Victoza at 1.2 mg or 1.8 mg daily for type 2 diabetes, and as Saxenda at 3.0 mg daily for chronic weight management. Same active ingredient, different doses, different registered jobs.

The mix-up has practical consequences. A dose that is right for diabetes is not the weight-management dose, so the brands cannot be swapped at the counter and a pharmacy will not substitute one for the other. If a pack does not match what your doctor confirmed, query it before injecting anything.

A third liraglutide product exists as well: Xultophy, a fixed combination of liraglutide and a long-acting insulin used in type 2 diabetes. It has no weight-management registration and sits entirely inside diabetes care.

Globally, Novo Nordisk has been scaling back Victoza production to free capacity for newer medicines, and Spotlight has reported on how such supply decisions reach South Africa. Availability can shift, which is one more reason treatment decisions run through a doctor and a licensed pharmacy rather than informal sourcing.

How well does liraglutide work for weight loss?

The main evidence is the SCALE Obesity and Prediabetes trial, a 56-week study of 3,731 adults without type 2 diabetes, published in the New England Journal of Medicine. Participants on liraglutide 3.0 mg lost an average of 8% of their body weight, compared with about 2.6% on placebo. Individual results vary.

In the same trial, around 63% of people on liraglutide lost at least 5% of their body weight, and roughly a third lost at least 10%. Individual results vary. All participants also followed a reduced-calorie diet and an activity plan, so the medicine supported those changes rather than replacing them.

SCALE was a programme rather than a single study. Separate trials tested the same 3.0 mg dose in people with type 2 diabetes, in keeping weight off after a diet-induced loss, and in obstructive sleep apnoea, and the results pointed the same way across them. Individual results vary.

How is liraglutide dosed?

Liraglutide is injected once a day, at any time of day, with or without food, ideally around the same time daily. For weight management, treatment starts low and steps up each week to reduce side effects, reaching the 3.0 mg maintenance dose over five weeks.

Your doctor may hold a dose step for longer if it is not well tolerated. The daily schedule is the main practical difference from the once-weekly medicines.

Holding a step is normal, not failure. If a new dose brings more nausea than you can live with, a doctor can keep you on the previous dose for another week or two before trying again; the timetable serves tolerance, not the other way around. The same pen dials every step from 0.6 mg to 3.0 mg, so a held step does not need a different pen.

What does the daily liraglutide routine look like?

One injection, once a day, at a time you can repeat. Morning suits many people because it attaches to an existing habit; evening works just as well. The medicine does not mind food or the clock, only inconsistency.

Each injection uses a fresh needle screwed onto the pen, and the site rotates between stomach, thigh and upper arm to keep the skin comfortable. The needles are short and fine, and the injection itself takes a few seconds.

Missed doses have clear rules in the product information. Remember within 12 hours of your usual time: take the dose. Past 12 hours: skip it and take the next one on schedule, never a double dose to catch up. More than three days missed: contact your doctor before restarting, because treatment usually resumes at the lowest step so the body can re-adjust.

Alarms beat willpower. A daily phone reminder, the pen stored near something you use at the same time every day, and a note of which injection site you used last will prevent most of what goes wrong in practice.

How do you store liraglutide during load shedding and travel?

Unopened pens live in the fridge at 2 to 8 degrees, in the original box. Once a pen is in use, the product information allows it to be kept in the fridge or out of it below 30 degrees, for up to one month. After a month in use the pen is discarded, even if medicine remains.

Load shedding is usually a non-issue inside those rules. A closed fridge holds a safe temperature for several hours, and an in-use pen on a shelf in a room under 30 degrees is within the label. The bigger risk is freezing: a pen that has frozen, including one pressed against the fridge's cooling element or an ice brick in a cooler bag, must be thrown away, and the damage cannot be seen.

For travel, pens go in hand luggage in an insulated pouch, never in checked baggage, where hold temperatures can drop below freezing. Crossing time zones with a daily medicine is manageable: keep home time for the injection and shift gradually, or agree a plan with your doctor before a long trip.

In summer, plan collection day. A pen in a hot car passes 30 degrees quickly, so collect last and refrigerate as soon as you are home.

How does liraglutide compare to newer weight-loss medicines?

Liraglutide is a daily GLP-1 injection. The newer medicines, semaglutide and tirzepatide, are given once a week and, on average, produced larger weight reductions in their own trials. That does not make liraglutide the wrong choice for everyone: dosing preference, tolerance, availability and a doctor's assessment all matter.

Semaglutide, for example, acts on the same single GLP-1 receptor as liraglutide but lasts long enough for weekly dosing. Tirzepatide goes further, adding a second gut hormone, GIP, on top of GLP-1. To understand that molecule, see what is semaglutide. For a side-by-side look at the daily and weekly options, read Saxenda vs Ozempic vs Mounjaro.

Liraglutide still has a place. It has the longest track record of the group, and for some people a daily routine, tolerance or availability makes it the sensible starting option. The decision is made with a doctor based on your health, not on the trial averages alone.

Can you switch between daily and weekly medicines?

Yes, in both directions, and it is a common conversation at reviews. People move from daily liraglutide to a weekly medicine for convenience or after results plateau, and sometimes the other way when a weekly option is out of stock or does not suit them. Tolerance, availability and results all feed the decision.

There is no unit conversion between molecules. Published consensus guidance on switching between GLP-1 medicines is consistent on the essentials: the change is planned by a doctor, the new medicine starts at an appropriate dose rather than a "matched" one, and side effects are watched through the changeover because the molecules clear the body at different speeds.

What you should not do is run two GLP-1 medicines at once, or bridge a gap with leftover pens from an old plan. Overlap raises side-effect risk without adding benefit.

If you are weighing a change, ask the prescribing doctor to plan the switch step by step.

How long do you take liraglutide?

Liraglutide is a long-term treatment for a long-term condition, not a short course. When the medicine stops, its effect on appetite stops too, and in trials many people regained weight after stopping. That is why it is used as an ongoing part of a plan rather than for a few weeks.

A doctor reviews whether to continue based on how you respond, how you tolerate it and your goals. Some people move to a once-weekly medicine if daily injections do not suit them, or if results plateau. Any change or stop is managed with a doctor rather than done abruptly on your own, so that diet and activity habits can carry more of the load over time.

How long has liraglutide been in use?

Longer than any other medicine usually discussed alongside it. Liraglutide was first authorised for type 2 diabetes in Europe in 2009 and in the United States in 2010 as Victoza, and the 3.0 mg weight-management dose followed as Saxenda from 2014. That is more than 15 years of routine use worldwide, with safety monitoring running the whole time.

The evidence grew with the years. The SCALE programme gave the weight-management dose its trial base, and a large cardiovascular outcomes trial in type 2 diabetes added long-term data at the diabetes doses. Newer GLP-1 medicines are still accumulating that kind of history.

That track record is part of why liraglutide remains a registered option even though newer medicines produced larger average weight loss in their own trials. Individual results vary, and the right option is decided by a doctor on assessment.

What are the side effects of liraglutide?

The most common side effects are digestive: nausea, diarrhoea, constipation, vomiting and indigestion. They are usually mild to moderate, most noticeable when the dose increases, and tend to settle as the body adjusts. Because liraglutide is taken daily, some people find early nausea more constant than with a weekly injection. Our guide to GLP-1 side effects and how to manage them covers practical steps.

Liraglutide is not suitable for everyone. It should not be used in pregnancy or while breastfeeding, or by people with a personal or family history of medullary thyroid cancer or MEN2 syndrome. A history of pancreatitis or gallbladder problems needs careful discussion with a doctor. Severe, persistent stomach pain can be a sign of pancreatitis: seek medical care immediately.

Low blood sugar is more likely if you also take insulin or a sulfonylurea, so a doctor reviews your other medicines before treatment and monitors you over time. Because liraglutide is a Schedule 4 medicine, that review and ongoing monitoring are part of every treatment plan, not an optional extra.

Two practical points help in the early weeks. Nausea eases for most people if meals are smaller and slower and fluids stay up, and dehydration from vomiting or diarrhoea is the main reason to check in with a doctor rather than push through. Report anything severe or persistent rather than waiting for the next review.

Frequently asked questions